Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

Abstract

Among patients who had a previous acute coronary syndrome and who were receiving high-intensity statin therapy, the risk of recurrent ischemic cardiovascular events was lower among those who received alirocumab than among those who received placebo. (Funded by Sanofi and Regeneron Pharmaceuticals; ODYSSEY OUTCOMES ClinicalTrials.gov number, NCT01663402 .).

Keywords

AlirocumabAcute coronary syndromeMedicineCardiologyInternal medicineMyocardial infarctionCholesterol

Affiliated Institutions

Related Publications

Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.

R B Sleight , Peter Sleight , Sarah Parish +3 more

17,187 patients entering 417 hospitals up to 24 hours (median 5 hours) after the onset of suspected acute myocardial infarction were randomised, with placebo control, between: (...

1988 PubMed 2873 citations

2023 ESC Guidelines for the management of acute coronary syndromes

Robert A. Byrne , Xavier Rosselló , J J Coughlan +97 more

peer reviewed

2023 European Heart Journal 3370 citations

2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Donna K. Arnett , Roger S. Blumenthal , Michelle A. Albert +15 more

1. The most important way to prevent atherosclerotic vascular disease, heart failure, and atrial fibrillation is to promote a healthy lifestyle throughout life. 2. A team-based ...

2019 Circulation 4477 citations

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

James Larkin , Vanna Chiarion‐Sileni , René González +28 more

BACKGROUND Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than ipilimumab alone in a trial involving patients with advance...

2019 New England Journal of Medicine 3500 citations

Publication Info

Year: 2018
Type: article
Volume: 379
Issue: 22
Pages: 2097-2107
Citations: 3201
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

3201

OpenAlex

Cite This

APA Style

                            
                                
                                    Gregory G. Schwartz, 
                                
                                    Philippe Gabríel Steg, 
                                
                                    Michael Szarek
                                
                                et al.
                            
                            (2018). 
                            Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. 
                            New England Journal of Medicine
                            , 379
                            (22)
                            , 2097-2107.
                            https://doi.org/10.1056/nejmoa1801174
                        

Identifiers

DOI: 10.1056/nejmoa1801174